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1 | INTRODUCTION
The rapid spread of the COVID-19 disease in the first months of 2020 caused high levels of anxiety in societies and 
hence resulted in panic buying, that is in hoarding of basic necessities including pharmaceuticals. Panic buying can be 
a rational reaction because potential supply disruptions, the anticipated restriction of movement, and the risk of disease 
transmission during store visits all have the effect of increasing optimal inventory holdings. Also, a crisis might lead to 
higher future prices, increasing current demand. However, the phenomenon of panic buying is socially costly because it 
can lead to shortages and thus heighten the anxiety about the pandemic (Keane & Neal, 2021). Shortages are especially 
costly for the vulnerable for whom shopping can be challenging, hence policy interventions may be necessary to address 
the detrimental impact of panic buying on them (Besson, 2020).
A growing body of the literature uses high-frequency transaction data to analyze the impact of the COVID-19 
pandemic on consumer spending (Baker et al., 2020; Carvalho et al., 2020; Chetty et al., 2020; O'Connell et al., 2020, 
among many others) but there is less large-scale empirical evidence on the impact of the pandemic on pharmaceuti-
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Abstract
We analyze the timing, magnitude, and income dependence of pharmaceuti-
cal panic buying around the outbreak of the COVID-19 pandemic in Hungary. 
We use district-level monthly and daily administrative data on detailed cate-
gories of pharmaceutical purchases, merge them to income statistics, and esti-
mate multilevel panel models. Our main results are as follows. First, the days 
of therapy (DOT) of pharmaceutical purchases increased by more than 30% in 
March 2020, when major lockdown measures were announced. This pattern 
holds for almost all categories of pharmaceuticals. Second, shortly after the 
panic reactions, the aggregate amount of pharmaceutical purchases returned 
to their preshock levels; however, the frequency of pharmacy visits decreased. 
Third, the panic buying reaction was significantly stronger in richer geographi-
cal areas, where—according to the daily data—people also reacted earlier to the 
pandemic-related news. Overall, the results suggest that panic buying of phar-
maceuticals can have detrimental effects on vulnerable populations.
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cal purchases. The available literature suggests that while the outbreak of the pandemic lead to a dramatic decrease 
in the utilization of outpatient healthcare services (Ahn et al., 2020; Cantor et al., 2020; Chatterji & Li, 2021; Ziedan 
et al., 2020), there was also a temporary surge in the purchases in pharmaceuticals. Using weekly wholesale data from 
Germany, Kostev and Lauterbach (2020) show evidence for a significant surge in purchases of medications for various 
chronic diseases shortly prior to the COVID-19 lockdown. Clement et al. (2021) document a surge in the demand for 
prescription drugs in March 2020 in the United States and also prove that the likelihood of discontinuing some medi-
cations increased and the number of new patients decreased after the spread of COVID-19. Our main contributions to 
this evolving literature are twofold. First, we estimate the exact timing and magnitude of panic buying of all categories 
of pharmaceuticals using administrative data of monthly and daily frequency from Hungary. Second, by observing the 
district of the patients, we investigate the socioeconomic differences in the patterns of pharmaceutical panic buying. 
While our focus is on the impacts of the COVID-19 shock, the results have a broader relevance—Loxton et al. (2020) 




In the first half of 2020, Hungary was moderately affected by the COVID-19 pandemic. The first COVID-19 cases 
were registered on March 5, 2020, the first death occurred on March 16, 2020. Until June 30, 2020, there were 4145 
cases and 585 deaths (out of the population of 9.8 million) (WHO, 2020). However, the rising numbers in nearby 
countries were perceived as a major threat for Hungary around the end of February 2020, and this was reflected by 
government communication and by the rising Google search intensity for the term “coronavirus” (“koronavírus,” 
in Hungarian) or “covid” at that time (Figure 1). On March 11, 2020, the Government declared state of emergency, 
banned large gatherings and ordered the closure of universities. On March 13, 2020, the Prime Minister announced 
the closure of schools as of March 16, 2020. Further lockdown measures were implemented on March 16, 2020, in-
cluding the closure of the borders to foreign travelers and the ban of all public events. Movement restrictions were 
introduced as of March 28, 2020: individuals were allowed to leave their homes only for essential needs, exercise, 
and work-related reasons. The restrictions were gradually eased from the end of April 2020, and the state of emer-
gency was lifted on June 17, 2020.
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F I G U R E  1  Google search intensity for “coronavirus” or “covid” in Hungary. Source: Google trends. Time period: January 1, 2020–June 
30, 2020. The search intensity indicator is set to 100 at its peak in the analyzed time period
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2.2 | Institutional background
In Hungary, user fees for prescription medications depend on the subsidy rates from the social security, which vary be-
tween 25% and 100%, and are slightly less than 50% on average. To get a prescription, patients have to contact a physician 
(typically the primary care physician) either at a clinic or by phone. Outpatient and inpatient healthcare visits do not 
require copayments. Physicians are allowed to provide prescription for at most 3-month supply for patients with chronic 
conditions and for 1 month otherwise (Gaál et al., 2011 provide a detailed overview of the Hungarian healthcare system.).
3 | DATA
The prescription drug data originate from the National Health Insurance Fund Administration, the single payer of the 
Hungarian healthcare system. The data are on the level of the 197 districts of Hungary (LAU1—local administrative unit 
level 1), with an average population of about 50,000 people.
First, we have monthly information on the district-level days of therapy (DOT) as well as the number of patients who 
bought medication for each first level ATC (Anatomical Therapeutic Chemical) group, and specifically for antidiabetics 
(ATC A10), antihypertensives (ATC C02–C03, C07–C09) and antidepressants (ATC N06A). In the analysis, we use per capi-
ta values, after adjustment to the average gender and age distribution of Hungary. Time coverage is January 2017–July 2020.
Second, we have district-level daily data on per capita DOT of antidiabetics, antihypertensives, and antidepressants. 
Time coverage is January 1, 2020–June 30, 2020.
We merge the dataset to the year 2017 values of district-level annual per capita taxable income, which originate from 
the National Regional Development and Spatial Planning Information System (TeIR).
4 | METHODS
First, we model log yit, the logarithm of gender- and age-adjusted per capita monthly consumption (DOT or number of 
patients) of a drug category in district i in month t (running from January 2017 until July 2020) as follows:
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where t is the time trend, wt is the number of working days in a month, mjt is the dummy for calendar month j(j = 1, 2, 
…, 12), m2020k,t is the dummy for month k in year 2020 (k = 1, 2, , …, 7 due to the date range), and pi is the district fixed 
effect. Note that all parameters (αq, βq, γqj, δqk) are specific to the income tertile of the district (indexed by q = 1, 2, 3). The 
parameters of interest are δqk, which show the income-dependent deviation of pharmaceutical purchases in the first 7 
months of 2020 from the trend and seasonality of the preceding 3 years.
Since the monthly shocks are correlated across districts, we model the (composite) error term as ut + ɛit, where ut is a 
random month effect, ɛit is the residual, and they are zero-mean, normally distributed, serially uncorrelated random var-
iables, also independent from each other. The model is estimated with maximum likelihood, using the mixed command 
of the Stata software package.
Second, for the daily data, let i denote the district and t the working days (we exclude purchases on weekends and na-
tional holidays, which altogether make up around 5% of total consumption.) Since the daily data only cover year 2020, we 
need to model intramonthly patterns in order to find the unusual days when purchases suddenly increased. As Figure 5 
shows, purchases are highly seasonal within a month, and reach their maximum on the 12th day (or on the last working 
day before), which is the time of the payment of pensions and other pension-type benefits in Hungary. Hence, we model 
log yit as follows:
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where djt is the dummy variable indicating the jth working day (−9 ≤ j ≤ 9) relative to the above defined peak day of drug 
purchases within a month, fjt indicates within-week seasonality (j = 1, 2, …, 5), while g−1,t and g+1,t denote the working 
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days before and after a national holiday, respectively, and pi is the district fixed effect. The variable si denotes the average 
logarithmic income of district i, standardized to have zero mean. Hence, the parameter θj1 allows intramonth seasonali-
ties to depend on district-level income.
We are interested in the deviation—and the income gradient of the deviation—of daily purchases from their usual 
patterns, hence we model the random time effect as u0t + u1tsi, where u0t and u1t are both zero mean, serially uncorrelat-
ed, normally distributed random variables, also independent from each other and from the ɛit residuals. A high value of 
u0t implies that purchases were unusually high on day t, while a high value of u1t indicates that the difference between 
large- and low-income districts was unusually high on that day. We estimate the model with maximum likelihood on data 
excluding February and March (the 2 months that may contain the periods of panic buying), and then predict u0t and u1t 
for the whole period.
5 | RESULTS
The descriptive plots of Figure 2 and the regression results of Figures A1 and A2 in the supplementary information 
material show that except for dermatologicals (ATC D) and anti-infectives for systemic use (ATC J), there was a clear 
temporary surge in the purchases of all categories of pharmaceuticals in March 2020. The magnitude of the jump ranged 
between 10% (e.g., antineoplastic and immunomodulating agents, ATC L) and 40% (alimentary tract and metabolism, 
ATC A). A regression of total DOT (of all pharmaceuticals) would yield an overall effect of 33% for March 2020 (not 
shown in the figures).
Focusing on three narrower groups of pharmaceuticals—antidiabetics, antihypertensives, and antidepressants—the 
descriptive and the regressions results of Figures 3 and 4 indicate that the relative surge in March 2020 was much larger 
for per capita DOT (20%–30%) than for the number of patients (10% or less). Also, in April–July 2020, the number of pa-
tients was well below the preshock level, while per capita DOT approached it. Hence, the amount of purchases per phar-
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F I G U R E  2  Time patterns of pharmaceutical purchases. Note: Gender- and age-adjusted monthly DOT per capita on the logarithmic 
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macy visit increased from March 2020 (per capita DOT was especially low in May 2020, when it became apparent that 
there would be no major disruption in pharmaceutical supply, hence patients could use up the stockpiled medications.)
We also see that the relative magnitude of panic buying was larger in the richer than in the smaller districts (for DOT, 
by 5%–6% larger in the upper tertile and by 4%–5% smaller in the lower tertile than in the middle tertile). Actually, a more 
detailed regression analysis by income decile shows that purchases of antidiabetic and antihypertensive medications 
increased disproportionately in the uppermost decile in March (by 8%–10% more than the median), while the differences 
in the other deciles were more gradual (see Figure A3 in the supplementary information material). Heterogeneity by 
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F I G U R E  3  Monthly DOT and number of patients per capita by income of the district. Note: Gender- and age-adjusted monthly DOT 






















































































































































































income holds for most other pharmaceutical categories as well (see Figures A1 and A2 in the supplementary information 
material). For the three specific pharmaceutical groups, the relative drop in the number of patients after March 2020 was 
also bigger in the richer districts (Figure 4).
The results based on the daily data (Figure 5) show that in the case of antidiabetics and antihypertensives, a signif-
icant income gradient (i.e., significantly positive u1t in Equation 2) appeared already at the end of February 2020, when 
the disease started to be considered as a major threat for Hungary (see Figure 1). We also estimate a positive income 
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F I G U R E  4  Monthly effects by income tertile on DOT and number of patients per capita. Note: Estimated monthly parameters (δqk in 
Equation 1) with 99% confidence intervals of gender- and age-adjusted logarithmic DOT and number of patients per capita for three drug 



























































































































































gradient on March 12–13, 2020, the days before the peak of panic-buying (16 March), indicating that the population of 
richer districts responded both earlier and more to the threat of COVID-19. Finally, the value of u0t on March 16 shows 
that antidiabetic and antihypertensive purchases were more than twice their usual values that day.
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F I G U R E  5  Results for DOT per capita based on daily data. Note: Daily logarithmic DOT per capita for three drug categories by income 
of the district (split at the median) and the difference by income (left column) and estimated daily random effects (u0t and u1t from Equa-
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We analyzed the timing, magnitude, and income dependence of pharmaceutical panic buying around the outbreak of 
the COVID-19 pandemic in Hungary. We found that the days of therapy of pharmaceutical purchases increased by more 
than 30% in the month when major lockdown measures were announced. This pattern holds for almost all categories of 
pharmaceuticals. The estimated relative increase is in line with the international evidence on the magnitude of panic 
buying of pharmaceuticals (Kostev & Lauterbach, 2020) and of other goods (Baker et al., 2020; O'Connell et al., 2020). 
After the panic reactions, the frequency of pharmacy visits decreased and the aggregate amount of pharmaceutical pur-
chases gradually returned to their preshock levels.
The panic buying reaction was significantly stronger in richer geographical areas, where people also reacted earlier 
to pandemic-related news. While we focused on income differences in panic reactions, income can be considered as a 
composite indicator of socioeconomic position, access to healthcare, and access to information. Indeed, district-level 
income in Hungary is strongly negatively correlated with, for example, the distance to the nearest pharmacy or with the 
district-level ratio of unfilled primary care practices (Bíró et al., 2021), but strongly positively correlated with the ratio of 
internet subscribers in the district (based on TeIR data). We conclude that the income gradient in pharmaceutical panic 
buying can be driven by three mechanisms: first, by direct income effects (poorer individuals cannot stockpile pharma-
ceuticals due to liquidity constraints); second, by better access to pharmacies and physicians in richer districts; and third, 
by better access to pandemic-related information in richer districts (as discussed in the Section 1, panic buying could be 
a rational reaction). While we cannot specifically test these mechanisms, it is worth noting that the income gradient of 
the panic reaction was similar for the three major drug categories examined, although the out-of-pocket cost per DOT 
was two to three times higher for antidiabetics than for antihypertensives and antidepressants (own calculations based 
on 2019 figures). This suggests that the income gradient is not solely driven by direct income effects (which would imply 
stronger gradient for more expensive pharmaceuticals).
Our results point out that panic buying of pharmaceuticals due to a major shock event can have detrimental effects 
on the vulnerable population who can react to the shock only with delays and to a smaller extent. This is particularly 
concerning if the panic eventually leads to temporary shortages of pharmaceuticals. Therefore, it is essential that gov-
ernments prevent unnecessary stockpiling primarily with the help of appropriate communication and quantity limits.
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